Dermata Therapeutics, Inc.
NASDAQ: DRMA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gerald T. Proehl
- Employees
- 8
- Headquarters
- San Diego, United States
- IPO year
- 2021
- Market cap
- $824.7K
- Website
- https://www.dermatarx.com
Loading DRMA…
Loading profile data…Frequently asked questions about DRMA
What does Dermata Therapeutics, Inc. (DRMA) do?
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinic...
Where does DRMA trade?
Dermata Therapeutics, Inc. (DRMA) trades on the NASDAQ Capital Market.
What sector is DRMA in?
Dermata Therapeutics, Inc. (DRMA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Dermata Therapeutics, Inc.?
Gerald T. Proehl is the chief executive officer of Dermata Therapeutics, Inc. (DRMA).
Where is Dermata Therapeutics, Inc. headquartered?
Dermata Therapeutics, Inc. is headquartered in United States.
Does DRMA pay a dividend?
Dermata Therapeutics, Inc. (DRMA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DRMA go public?
Dermata Therapeutics, Inc. (DRMA) completed its initial public offering in 2021.